Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC)

Current Medical Research and Opinion

Volumn 28, Issue 8, 2012, Pages 1263-1279

  Riemsma, Rob ^a   Forbes, Carol A ^a   Amonkar, Mayur M ^b   Lykopoulos, Konstantinos ^c   Diaz, Jose R ^c   Kleijnen, Jos ^a,d   Rea, Daniel W ^e  

^a KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Advanced or metastatic breast cancer; Aromatase inhibitor; First line treatment; HER2; HR; Lapatinib

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; DROLOXIFENE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; LAPATINIB; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB;

ARTHRALGIA; BONE PAIN; BREAST CANCER; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HOT FLUSH; HUMAN; META ANALYSIS; NAUSEA; OBJECTIVE RESPONSE RATE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL; SYSTEMATIC REVIEW; TIME TO PROGRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NITRILES; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRIAZOLES;

EID: 84864539047     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.707643     Document Type: Review

References (45)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA-Cancer J Clin 2011;61:69-90
2. Anderson WF, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002;76:27-36
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
4. Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD003370. DOI: 10.1002/14651858. CD003370.pub3
5. Arpino G, Weichmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008;29:217-33
6. Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008;456:663-6
7. Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003;21:1967-72
8. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:S9-15
9. Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 2004;10:3621-8
10. Johnston S, Pippen Jr J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46
11. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-37
12. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 updated March 2011: The Cochrane Collaboration, 2011
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48
15. Bucher HC, Guyatt GH, Griffiths LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
16. Puhan MA, Bachmann LM, Kleijnen J, et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: A network meta-analysis. BMC Med 2009;7:2
17. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758-67
18. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-57
19. Mouridsen HT. Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 2007;105:19-29
20. Nabholtz JM, Bonneterre J, Buzdar A, et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003;39:1684-9
21. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008;26:4883-90
22. Howell A, Robertson JFR, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-13
23. Buzdar A, Hayes D, El-Khoudary A, et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 2002;73:161-75
24. Falkson CI, Falkson HC. A randomised study of CGS 16949A (fadrozole) versus tamoxifen previously untreated postmenopausal patients with metastatic breast cancer. Ann Oncol 1996;7:465-9
25. Thurlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer: prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88 Ann Oncol 1996;7:471-9
26. Stuart NS, Warwick J, Blackledge GR, et al. A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer 1996;32A:1888-92
27. Willsher PC, Robertson FR, Armitage NC, et al. Locally advanced breast cancer: long-term results of a randomised trial comparing primary treatment with tamoxifen or radiotherapy in post-menopausal women. Eur J Surg Oncol 1996;22:34-7
28. Milla-Santos A, Milla L, Rallo L, et al. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat 2001;65:119-24
29. Pyrhonen S, Valavaara R, Modig H, et al. Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: A randomized double-blind, the 'nordic' phase III study. Br J Cancer 1997;76:270-7
30. Gill PG, Gebski V, Snyder R, et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol 1993;4:741-4
31. Forbes JF. A randomized trial of sequential antioestrogen/cytotoxic chemotherapy, versus sequential cytotoxic chemotherapy/antioestrogen therapy, versus combined modality therapy, in 339 patients with advanced breast cancer. Rev Endocr Relat Cancer 1986;Supplement 18:43-50
32. Milla-Santos A, Milla L, Portella J, et al. Anastrozole versus tamoxifen as firstline therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, phase III study. Am J Clin Oncol 2003;26:317-22
33. Perez-Carrion R, Alberola Candel V, Calabresi F, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994;5:S19-24
34. Azienda Ospedaliera Ordine Mauriziano di Torino. Efficacy study of single agent trastuzumab or lapatinib to treat HER2-overexpressing breast cancer (HERLAP). In: ClinicalTrials.gov Internet. Bethesda (MD): National Library of Medicine (US), 2009 Cited 04/10/11. Available from: http://clinicaltrials. gov/ct2/show/NCT00842998: NCT00842998
35. Southwest Oncology Group. Phase III randomized study of anastrozole with or without fulvestrant as first-line therapy in postmenopausal women with metastatic breast cancer. In: ClinicalTrials.gov Internet. Bethesda (MD): National Library of Medicine (US), 2004 Cited 04/10/11. Available from: http://clinicaltrials. gov/ct2/show/NCT00075764: NCT00075764
36. Robertson JFR, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-5
37. Kaufman B. Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2 positive, hormonedependent metastatic breast cancer (MBC). Presented at European Society for Medical Oncology (ESMO) Congress; 29 Sept/3 Oct 2006; Istanbul, Turkey
38. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16
39. Nabholtz JM. Advanced breast cancer updates on anastrozole versus tamoxifen. J Steroid Biochem Mol Biol 2003;86:321-5
40. Panageas KS, Ben-Porat L, Dickler MN, et al. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007;99:428-32
41. Carroll KJ. Analysis of progression-free survival in oncology trials: some common statistical issues. Pharm Stat 2007;6:99-113
42. Committee for Medicinal Products for Human Use (CHMP). Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man (CHMP/EWP/205/95 REV.3). Methodological considerations for using progressionfree survival (PFS) as primary endpoint in confirmatory trials for registration. London: European Medicines Agency (EMEA), 2008
43. Chakravarty A, Sridhara R. Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues. Stat Methods Med Res 2008;17:515-18
44. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis. Cancer 2001;92:2247-58
45. Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;338:B1147